Recommendation history:the last 12 months
Every investment recommendation disseminated in the last 12 months, including the ones that expired, were superseded or ended in a loss.
The 12-month record
279entries
on 144 stocks
- in force
- 144
- superseded
- 135
- expired
- 0
Direction of the rating
- Positive69
- Neutral91
- Negative119
Producer and distributor: Ploutos AI
Responsible for producing the research: Nikolaos Drongitis, Founder & Head of Investment Research
Updated November 15, 2026, 01:11 UTC
Past performance does not guarantee future results. Realized returns can differ materially from the tracked numbers shown.
Every entry
Newest first, with every field the disclosure names.
- MPTMedical Properties Trust Inc.RatingUnderperformnegative
- MPTMedical Properties Trust Inc.RatingUnderperformnegative
- NVDANVIDIA CORPRatingMarket Performneutral
- AUPHAurinia Pharmaceuticals Inc.RatingOutperformpositive
- MRVLMarvell Technology, Inc.RatingUnderperformnegative
- INTCINTEL CORPRatingUnderperformnegative
- AMZNAmazon Com IncRatingUnderperformnegative
- RKLBRocket Lab CorpRatingUnderperformnegative
- PLTRPalantir Technologies Inc.RatingUnderperformnegative
- NVDANVIDIA CORPRatingMarket Performneutral
| Security | Dissemination | Type and ISIN | Rating | Price and fair value | Horizon and status | Responsible and MAR | Changes |
|---|---|---|---|---|---|---|---|
| MPTMedical Properties Trust Inc. | 2026-11-1317:24 UTC | US58463J3041Common Stock | Underperformnegative | $1.632026-11-13Fair value— | ActiveLong-term (365 days)valid until 2027-11-13 UTCStatusNegative rating tracked (evaluation pending) | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeIn scope | NoneCorrectionNone |
| MPTMedical Properties Trust Inc. | 2026-11-1317:12 UTC | US58463J3041Common Stock | Underperformnegative | $1.642026-11-13Fair value— | SupersededMedium-term (180 days)valid until 2027-05-12 UTCStatusNegative rating tracked (evaluation pending) | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeIn scope | 2026-11-13 UTCCorrectionNone |
| NVDANVIDIA CORP | 2026-11-1317:03 UTC | US67066G1040Common Stock | Market Performneutral | $160.252026-11-13Fair value$61.14 to $209.10 | ActiveLong-term (365 days)valid until 2027-11-13 UTCStatusNo position tracked | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeIn scope | NoneCorrectionNone |
| AUPHAurinia Pharmaceuticals Inc. | 2026-11-0812:39 UTC | CA05156V1022Common Stock | Outperformpositive | $16.462026-11-06Fair value$35.11 to $55.93 | ActiveLong-term (365 days)valid until 2027-11-08 UTCStatusNo position tracked | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeIn scope | NoneCorrectionNone |
| MRVLMarvell Technology, Inc. | 2026-11-0812:21 UTC | — | Underperformnegative | $141.202026-11-06Fair value$46.63 to $73.46 | ActiveMedium-term (180 days)valid until 2027-05-07 UTCStatusNegative rating tracked (evaluation pending) | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeNot determined | NoneCorrectionNone |
| INTCINTEL CORP | 2026-11-0812:21 UTC | — | Underperformnegative | $56.282026-11-06Fair value$7.98 to $31.50 | ActiveMedium-term (180 days)valid until 2027-05-07 UTCStatusNegative rating tracked (evaluation pending) | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeNot determined | NoneCorrectionNone |
| AMZNAmazon Com Inc | 2026-11-0307:25 UTC | US0231351067Common Stock | Underperformnegative | $245.632026-11-02Fair value$67.55 to $196.47 | ActiveLong-term (365 days)valid until 2027-11-03 UTCStatusNegative rating tracked (evaluation pending) | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeIn scope | NoneCorrectionNone |
| RKLBRocket Lab Corp | 2026-11-0218:49 UTC | — | Underperformnegative | $52.372026-11-02Fair value$2.83 to $4.91 | ActiveMedium-term (180 days)valid until 2027-05-01 UTCStatusNegative rating tracked (evaluation pending) | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeNot determined | NoneCorrectionNone |
| PLTRPalantir Technologies Inc. | 2026-11-0218:49 UTC | US69608A1088Common Stock | Underperformnegative | $183.312026-11-02Fair value$26.42 to $54.10 | ActiveMedium-term (180 days)valid until 2027-05-01 UTCStatusNegative rating tracked (evaluation pending) | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeIn scope | NoneCorrectionNone |
| NVDANVIDIA CORP | 2026-11-0218:49 UTC | US67066G1040Common Stock | Market Performneutral | $205.852026-11-02Fair value$61.14 to $209.10 | SupersededMedium-term (180 days)valid until 2027-05-01 UTCStatusNo position tracked | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeIn scope | 2026-11-13 UTCCorrectionNone |
The full analysis
What do a company's filings show?
Every rating in the table came out of an analysis of the company's SEC filings. The full Ploutos AI analysis reads everything a company has filed and shows what stands behind its figures, with a source for each one.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which recommendations does the table include?
The table contains every investment recommendation disseminated during the previous 12 months that falls within the scope of this record, without selection by outcome. For additional transparency, Ploutos AI may also display recommendations for instruments to which it voluntarily applies the same standards. These are separately identified.
What is shown for each recommendation?
Each entry shows: dissemination date and time with timezone, issuer and instrument, ticker and ISIN where available, the name and job title of the person responsible for production, rating and direction, market price at dissemination with its own timestamp, fair value or price target where published, time horizon and validity period, current status, any superseding recommendation and any visible correction.
What happens when a recommendation is superseded or corrected?
When a recommendation is superseded or corrected, the original entry stays as published: it is not deleted or silently altered, and the correction is shown separately.
Do I need to sign up to see the full record?
The list is available free of charge and without registration. Filters or pagination do not restrict access to the complete record.
Why are some analyses not in the table?
Outside the table: 37 analyses that left no entry on the list, either because they rated no stock or because the published output cannot be read, and 0 ratings with no recognised tier. The counts are published so that nothing is removed in silence.
Why are the Market Radar picks not here?
The weekly Market Radar lists are not included here. Radar selections carry no individual rating tier and are recorded separately.
The public record
The pages where the method shows in practice, in full and unselected.